PLUS THERAPEUTICS, INC.

Developing targeted radiotherapeutics for hard-to-treat cancers like glioblastoma and solid tumors.

PSTV | US

Overview

Corporate Details

ISIN(s):: US23283K2042 (+1 more)
LEI:
Country:: United States of America
Address:: 4200 MARATHON BLVD., 78756 AUSTIN
Website:: http://www.plustherapeutics.com/
Sector:: Manufacturing
Industry:: Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company focused on developing targeted radiotherapeutics for difficult-to-treat cancers in adults and children. The company's proprietary platform is designed to deliver a single, high-dose of radiation directly to tumors while minimizing damage to healthy tissue. This is achieved by encapsulating Rhenium radioisotopes within novel delivery systems like nanoliposomes and biodegradable microspheres. Its lead drug candidate, REYOBIQ™ (rhenium Re186 obisbemeda), targets central nervous system (CNS) cancers, including glioblastoma and leptomeningeal metastases. The company's pipeline also includes a next-generation therapy for solid organ cancers, such as liver cancer.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Quick Filters:

Filters

Filing Type

Language

Start date

End date

Clear

Bulk Actions:

	Date	Filing	Language	Size	Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all PLUS THERAPEUTICS, INC. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for PLUS THERAPEUTICS, INC.

This data is available as part of our premium data solutions. Contact our team for access.

Request This Data

Need More History? Access decades of standardized financials for PLUS THERAPEUTICS, INC. via our API.

Get Historical Data →

Insider Transactions

Date	Insider Name	Position	Type	Shares	Value
No insider transactions recorded for this company.

Peer Companies

Company	Country	Ticker
Kiniksa Pharmaceuticals International, plc Develops and commercializes immune-modulating therapies for debilitating diseases with unmet needs.	United States of America	KNSA
KIORA PHARMACEUTICALS INC Developing advanced small molecule therapies for vision-threatening retinal diseases.	United States of America	KPRX
KISSEI PHARMACEUTICAL CO.,LTD. Develops innovative drugs for urology, renal diseases, and rare or intractable diseases.	Japan	4547
Klaria Pharma Holding AB Develops oral films for non-invasive drug delivery as an alternative to injections and sprays.	Sweden	KLAR
Klotho Neurosciences, Inc. Advancing gene and cell therapies for neurodegenerative disorders, cancer, and chronic diseases.	United States of America	KLTO
KOA SHOJI HOLDINGS CO.,LTD. Imports APIs and manufactures generic drugs for Japan's pharmaceutical industry.	Japan	9273
KOBAYASHI PHARMACEUTICAL CO.,LTD. Manufactures OTC pharma, personal care, and household goods for niche consumer markets.	Japan	4967
Kodiak Sciences Inc. Developing durable biologics to treat high-prevalence retinal diseases and prevent blindness.	United States of America	KOD
Kohjin Bio Co., Ltd. A CDMO providing culture media & bioservices for cell therapy, research, and diagnostics.	Japan	177A
KOLON LIFE SCIENCE Inc. Develops gene therapies and manufactures APIs, providing global CDMO/CMO services.	South Korea	102940